Opexa Therapeutics (OPXA) 1.49 $OPXA
Opexa Therapeutics Announces News Release and Conference Call to Discuss First Quarter 2014 Financial Results
Business Wire - Mon May 12, 7:01AM CDT
Opexa Therapeutics, Inc. (NASDAQ: OPXA), a biotechnology company developing Tcelna(R), a novel T-cell immunotherapy for the treatment of multiple sclerosis (MS), today announced that the Company will report financial results for the three months ended March 31, 2014 after the close of trading on Wednesday, May 14th. The company will also conduct a conference call and webcast to discuss financial results and provide a corporate update at 5:00 P.M. EDT on Wednesday, May 14th.
RedChip TV Announces Lineup for This Week's Show on Fox Business and Bloomberg
GlobeNewswire - Thu May 08, 9:20AM CDT
RedChip Companies, Inc. ("RedChip"
, an international small-cap research, investor relations, and media company, today announced that "The RedChip Money Report: Small Stocks Big Money" television program will feature two emerging growth companies on Fox Business nationwide on Thursday, May 8, 2014 at 10:00 p.m. Pacific (1 a.m. EDT). The show will also air on Bloomberg U.K. Saturday, May 10, 2014 at 12:30 a.m. GMT; on Bloomberg Europe on Sunday, May 11, 2014 at 8:30 a.m. and 3:30 p.m. GMT; and on Bloomberg Asia on Sunday May 11, 2014 at 3:30 p.m. HKT.
Type 1 Diabetes (Juvenile Diabetes) - Pipeline Review, H1 2014: 79 Companies Profiled
M2 - Wed May 07, 12:21PM CDT
Research and Markets (http://www.researchandmarkets.com/research/2d32kc/type_1_diabetes) has announced the addition of the "Type 1 Diabetes (Juvenile Diabetes) - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Type 1 Diabetes (Juvenile Diabetes), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Type 1 Diabetes (Juvenile Diabetes) and special features on late-stage and discontinued projects. The report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Mentioned: - Alcon, Inc. - Johnson & Johnson - Boehringer Ingelheim GmbH - Osiris Therapeutics, Inc. - Sanofi - AstraZeneca PLC - Eli Lilly and Company - Inovio Pharmaceuticals, Inc. - MedImmune, LLC - Daiichi Sankyo Company, Limited - Merck & Co., Inc. - AbGenomics International, Inc. - Novo Nordisk A/S - Generex Biotechnology Corporation - BioLineRx, Ltd. - Kissei Pharmaceutical Co., Ltd. - Pfizer Inc. - Cell Therapeutics, Inc. - Hadasit Medical Research Services & Development Ltd - Biodel Inc. - MannKind Corporation - Halozyme Therapeutics, Inc. - Merck KGaA - Evotec AG - Karo Bio AB - Ligand Pharmaceuticals, Inc. - Opexa Therapeutics, Inc. - Compugen Ltd. - Oramed Pharmaceuticals, Inc. - Lexicon Pharmaceuticals, Inc. For more information visit http://www.researchandmarkets.com/research/2d...1_diabetes
Relapsing Remitting Multiple Sclerosis (RRMS) - Pipeline Review, H1 2014: 23 Companies and 33 Drugs Profiled
M2 - Wed May 07, 12:10PM CDT
Research and Markets (http://www.researchandmarkets.com/research/p7dbhq/relapsing) has announced the addition of the "Relapsing Remitting Multiple Sclerosis (RRMS) - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Relapsing Remitting Multiple Sclerosis (RRMS), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Relapsing Remitting Multiple Sclerosis (RRMS) and special features on late-stage and discontinued projects. The report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Companies Involved in Therapeutics Development - AbbVie Inc. - Actelion Ltd - Allozyne, Inc. - Amarna Therapeutics B.V. - Biogen Idec Inc. - Cognosci, Inc. - Eli Lilly and Company - F. Hoffmann-La Roche Ltd. - Genmab A/S - GlaxoSmithKline plc - MedImmune, LLC - Merck KGaA - Mitsubishi Tanabe Pharma Corporation - Neurotec Pharma SL - Novartis AG - Nuron Biotech, Inc. - Opexa Therapeutics, Inc. - Receptos, Inc. - RedHill Biopharma Ltd. - Synthetic Biologics, Inc. - Teva Pharmaceutical Industries Limited - Trophos SA - XenoPort, Inc. Drug Profiles: - laquinimod sodium - dimethyl fumarate - laquinimod sodium - fingolimod hydrochloride - ocrelizumab - interferon beta-1b - daclizumab - RPC-1063 - Epigallocatechin Gallate - GSK-239512 - siponimod - tabalumab - firategrast - ponesimod - plovamer acetate - estriol - imilecleucel-t - olesoxime - ofatumumab - RNS-60 - (rifabutin clarithromycin clofazimine) - diazoxide - MT-1303 - Boswellic Acids - VAY-736 - MEDI-551 - interferon beta-1b pegylated - XP-23829 - Pegylated Interferon-Beta-1b - COG-133 For more information visit http://www.researchandmarkets.com/research/p7dbhq/relapsing
Opexa Therapeutics to Attend the American Academy of Neurology Annual Meeting
Business Wire - Tue Apr 22, 7:01AM CDT
Opexa Therapeutics, Inc. (NASDAQ: OPXA), a biotechnology company developing Tcelna(R) (imilecleucel-T), a novel T-cell immunotherapy for the treatment of multiple sclerosis (MS), today announced its participation at the American Academy of Neurology (AAN) 2014 Annual Meeting taking place from April 26 to May 3, 2014 in Philadelphia. The AAN Annual Meeting is the world's largest gathering of neurologists, featuring breakthrough scientific research.
Brinson Patrick Re-launches Research Department
PR Newswire - Thu Apr 10, 7:21AM CDT
Brinson Patrick Securities Corporation ("Brinson Patrick" announced today that the firm has re-launched its equity research department with the recent initiation of coverage on several life sciences companies. The research effort is being spearheaded by Christopher James, M.D., Managing Director and Senior Equity Research Analyst.
Lawsuits, Clinical Studies, Financial Results, and Stock Movements - Analyst Notes on Idenix, BG Medicine, Progenics, Omeros, and Opexa
PR Newswire - Fri Mar 21, 7:00AM CDT
Today, Analysts Review released its analysts' notes regarding Idenix Pharmaceuticals Inc. (NASDAQ: IDIX), BG Medicine, Inc. (NASDAQ: BGMD), Progenics Pharmaceuticals Inc. (NASDAQ: PGNX), Omeros Corporation (NASDAQ: OMER), and Opexa Therapeutics, Inc. (NASDAQ: OPXA). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.AnalystsReview.com/register http://www.analystsreview.com/register
Opexa Therapeutics Appoints Prof. Hans-Peter Hartung and Timothy Barabe to the Board of Directors
Business Wire - Thu Mar 20, 7:01AM CDT
Opexa Therapeutics, Inc. (NASDAQ: OPXA), a biotechnology company developing Tcelna(R), a novel T-cell immunotherapy for the treatment of multiple sclerosis (MS), today announced the addition of two highly experienced individuals to join the Company's Board of Directors. Hans-Peter Hartung, MD, PhD, FRCP, a world leading clinician and expert in the treatment of Multiple Sclerosis and other neurological diseases, and Timothy Barabe, a proven CFO with global operational and financial expertise, have each been appointed to the Company's Board of Directors, effective March 19th.
Global Stem Cell Umbilical Cord Blood (UCB) Market to 2020
M2 - Mon Mar 10, 7:45AM CDT
Research and Markets (http://www.researchandmarkets.com/research/gsw6jj/global_stem_cell) has announced the addition of the "Global Stem Cell Umbilical Cord Blood (UCB) Market to 2020" report to their offering. The market is expected to reach revenue of $56.4 billion by 2020, growing at CAGR of 33.4% during 2013 to 2020 The study observed that the global umbilical cord blood stem cell market is forecasted to reach market value over $11.5 billion in 2014 from $ 6.5 billion in 2012. Developments and approvals for novel cord blood stem cells therapies is expected to drive the market growth. The storage service market was valued at $7.4 billion in 2013. Increase in prevalence rate of chronic diseases such as cancer, diabetes, blood disease, immune disease, metabolic disease etc. has increased the need of cost effective and efficient way of treatment. However, cord blood stem cells have the potential to treat these chronic diseases effectively. These stem cells have special property of higher cell count in lower blood volume. Collection of these stem cells is much easier than other stem cells and could be stored in specialized preservation facilities called as Cord Blood Stem Cell Banks.Cord blood stem cells market is in its emerging phase. Significant applications of stem cells in the treatment of various disorders will be commercialized very soon as most of them are in the last phase of clinical trials. Patents for collection techniques and therapeutics methods are approved by respective government of developed countries however patents for UCB stem cells are comparatively less in developing economies. According to lead analyst Debbie Shields, the geographic analysis shows that the North American market for cord blood stem cell would account for approx. 44% of total revenue generated by the cord blood market in 2013. However, much expected growth is to occur in Asia-Pacific regions during the forecast period, because of growing demand for chronic disease treatments and widely increasing awareness levels. This report study offers updated review about major market players present in this market such as researcher based pharmaceutical companies and therapeutics services companies. Key Market Segments Global Stem cell UCB market by storage - Public cord blood banks - Private cord blood banks - Public Vs. Private UCB banks Global Stem cell UCB market by Diseases - Cancer/ Oncology diseases - Acute Leukemia - Chronic Leukemia - High Risk Solid Tumors - Myelodysplastic Syndrome - Blood diseases - Aplastic Anemia - Beta Thalassemia - Sickle Cell disease - Immune Disorders - Leukocyte Adhesion Deficiency - Hystiocytic Disorders - Wiskott-Aldrich - Metabolic Disorders - Krabbe Disease - Hurler Syndrome - Sanfilippo Syndrome - Other diseases - Osteopetrosis - Hemophagoyticlymphohistiocytosis Global Stem cell UCB market by Technology - Stem Cell Transplant - Autologous transplant - Allogenic transplant - Transplant Medicine - Regenerative Medicine - Others - Cord Blood Banking - Blood Transfusion - Cell Based Genetics Companies Mentioned - Advanced Cell Technology Inc. (USA) - Athersys Inc. - California Stem Cell - Cytori Therapeutics Inc. - Geron Corporation - Mesoblast Limited - NeoStem Inc. - Opexa Therapeutics Inc. - Osiris Therapeutics - Pluristem Therapeutics Inc. For more information visit http://www.researchandmarkets.com/research/gs..._stem_cell
Opexa Therapeutics Reports Year End 2013 Financial Results and Provides Corporate Update
Business Wire - Thu Feb 27, 3:20PM CST
Opexa Therapeutics, Inc. (NASDAQ: OPXA), a biotechnology company developing a novel T-cell immunotherapy for multiple sclerosis (MS), today reported financial results for the year ended December 31, 2013, and provided an overview of recent corporate developments.
Opexa Therapeutics Announces News Release and Conference Call Schedule to Discuss Year End 2013 Financial Results
Business Wire - Wed Feb 26, 7:02AM CST
Opexa Therapeutics, Inc. (NASDAQ: OPXA), a biotechnology company developing Tcelna(R), a novel T-cell immunotherapy for the treatment of multiple sclerosis (MS), today announced that the Company will report financial results for the year ended December 31, 2013, at the close of trading on Thursday, February 27, 2014. The Company will also conduct a conference call and webcast to discuss financial results and provide a corporate update at 4:30 P.M. EST on Thursday, February 27.
Opexa Therapeutics CEO to Present at the 2014 Leerink Global Healthcare Conference
Business Wire - Tue Feb 11, 1:16PM CST
Opexa Therapeutics, Inc. (NASDAQ: OPXA), a biotechnology company developing Tcelna(R), a novel T-cell immunotherapy for the treatment of multiple sclerosis (MS), today announced that Neil K. Warma, President and Chief Executive Officer, will present at the 2014 Leerink Global Healthcare Conference on Wednesday, February 12, 2014, at 1:00 p.m. EST in the Metropolitan Suite. The conference will be held at the Waldorf-Astoria Hotel in New York, NY.
Opexa Therapeutics to Present at the 16th Annual BIO CEO & Investor Conference
Business Wire - Wed Jan 29, 8:00AM CST
Opexa Therapeutics, Inc. (NASDAQ: OPXA), a biotechnology company developing Tcelna(R), a novel T-cell immunotherapy for the treatment of multiple sclerosis (MS), today announced that Neil K. Warma, President and Chief Executive Officer, will present at the 16th Annual BIO CEO & Investor Conference on Monday, February 10, 2014, at 11:30 a.m. EST in the Conrad Room. The conference will be held at the Waldorf=Astoria Hotel in New York, NY.
Opexa Therapeutics Chief Scientific Officer Invited as Guest Speaker at the Phacilitate Cell & Gene Therapy Forum
Business Wire - Thu Jan 23, 8:00AM CST
Opexa Therapeutics, Inc. (NASDAQ: OPXA), a biotechnology company developing Tcelna(R), a novel T-cell immunotherapy for the treatment of multiple sclerosis (MS), today announced that Don Healey, Ph.D., Opexa's Chief Scientific Officer, has been invited as a guest speaker to participate in the Phacilitate Cell & Gene Therapy Forum. The event will take place January 27-29, 2014, at The Grand Hyatt in Washington, DC.
Opexa Therapeutics Inc concludes public offering of 4.12m common shares, including the exercise of over-allotment option
M2 - Tue Dec 24, 8:57AM CST
Biotechnology company Opexa Therapeutics Inc (NasdaqCM:OPXA) revealed on Monday the completion of an underwritten public offering of 4,120,000 shares of its common stock,
Opexa Therapeutics, Inc. Announces Closing of Public Offering of Common Stock and Full Exercise of Underwriters' Option to Purchase Additional Shares
Business Wire - Mon Dec 23, 9:18AM CST
Opexa Therapeutics, Inc. (NASDAQ: OPXA), a biotechnology company developing Tcelna(R), a patient-specific T-cell immunotherapy for the treatment of multiple sclerosis (MS), today announced the closing of the previously announced underwritten public offering of 4,120,000 shares of its common stock, including the full exercise of the over-allotment option granted to the underwriters to purchase an additional 618,000 shares of its common stock, at a price to the public of $1.70 per share. The gross proceeds to Opexa from this offering were $8,054,600, before deducting underwriting discounts and commissions and other estimated offering expenses and including the full exercise of the over-allotment option. All of the shares in the offering were sold by Opexa.
Apricus Biosciences Inc receives national phase approval for erectile dysfunction cream Vitaros in France
M2 - Fri Dec 20, 5:36AM CST
Pharmaceutical company Apricus Biosciences Inc (NasdaqCM:APRI) reported on Thursday the receipt of National Agency for Medicines and Health Products Safety's (ANSM) national phase approval for Vitaros for the treatment of patients with erectile dysfunction (ED) in France.
Opexa Therapeutics Inc prices public offering at USD1.70 per share
M2 - Wed Dec 18, 3:24AM CST
Biotechnology company Opexa Therapeutics Inc (NasdaqCM:OPXA) said on Tuesday that it has priced an underwritten public offering of 4.12m shares of its common stock.
Opexa Therapeutics, Inc. Announces Pricing of Public Offering of Common Stock
Business Wire - Tue Dec 17, 8:15PM CST
Opexa Therapeutics, Inc. (NASDAQ:OPXA), a biotechnology company developing Tcelna(R), a patient-specific T-cell immunotherapy for the treatment of multiple sclerosis (MS), today announced the pricing of an underwritten public offering of 4.12 million shares of its common stock at a price to the public of $1.70 per share. The gross proceeds to Opexa from this offering are expected to be approximately $7 million, before deducting underwriting discounts and commissions and other estimated offering expenses. All of the shares in the offering are to be sold by Opexa. Opexa has also granted the underwriters a 45-day option to purchase up to an additional 618,000 shares of common stock to cover over-allotments, if any. The offering is expected to close on or about December 23, 2013, subject to customary closing conditions.
Opexa Therapeutics Announces News Release and Conference Call to Discuss First Quarter 2014 Financial Results
Business Wire - Mon May 12, 7:01AM CDT
Opexa Therapeutics, Inc. (NASDAQ: OPXA), a biotechnology company developing Tcelna(R), a novel T-cell immunotherapy for the treatment of multiple sclerosis (MS), today announced that the Company will report financial results for the three months ended March 31, 2014 after the close of trading on Wednesday, May 14th. The company will also conduct a conference call and webcast to discuss financial results and provide a corporate update at 5:00 P.M. EDT on Wednesday, May 14th.
RedChip TV Announces Lineup for This Week's Show on Fox Business and Bloomberg
GlobeNewswire - Thu May 08, 9:20AM CDT
RedChip Companies, Inc. ("RedChip"
, an international small-cap research, investor relations, and media company, today announced that "The RedChip Money Report: Small Stocks Big Money" television program will feature two emerging growth companies on Fox Business nationwide on Thursday, May 8, 2014 at 10:00 p.m. Pacific (1 a.m. EDT). The show will also air on Bloomberg U.K. Saturday, May 10, 2014 at 12:30 a.m. GMT; on Bloomberg Europe on Sunday, May 11, 2014 at 8:30 a.m. and 3:30 p.m. GMT; and on Bloomberg Asia on Sunday May 11, 2014 at 3:30 p.m. HKT. Type 1 Diabetes (Juvenile Diabetes) - Pipeline Review, H1 2014: 79 Companies Profiled
M2 - Wed May 07, 12:21PM CDT
Research and Markets (http://www.researchandmarkets.com/research/2d32kc/type_1_diabetes) has announced the addition of the "Type 1 Diabetes (Juvenile Diabetes) - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Type 1 Diabetes (Juvenile Diabetes), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Type 1 Diabetes (Juvenile Diabetes) and special features on late-stage and discontinued projects. The report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Mentioned: - Alcon, Inc. - Johnson & Johnson - Boehringer Ingelheim GmbH - Osiris Therapeutics, Inc. - Sanofi - AstraZeneca PLC - Eli Lilly and Company - Inovio Pharmaceuticals, Inc. - MedImmune, LLC - Daiichi Sankyo Company, Limited - Merck & Co., Inc. - AbGenomics International, Inc. - Novo Nordisk A/S - Generex Biotechnology Corporation - BioLineRx, Ltd. - Kissei Pharmaceutical Co., Ltd. - Pfizer Inc. - Cell Therapeutics, Inc. - Hadasit Medical Research Services & Development Ltd - Biodel Inc. - MannKind Corporation - Halozyme Therapeutics, Inc. - Merck KGaA - Evotec AG - Karo Bio AB - Ligand Pharmaceuticals, Inc. - Opexa Therapeutics, Inc. - Compugen Ltd. - Oramed Pharmaceuticals, Inc. - Lexicon Pharmaceuticals, Inc. For more information visit http://www.researchandmarkets.com/research/2d...1_diabetes
Relapsing Remitting Multiple Sclerosis (RRMS) - Pipeline Review, H1 2014: 23 Companies and 33 Drugs Profiled
M2 - Wed May 07, 12:10PM CDT
Research and Markets (http://www.researchandmarkets.com/research/p7dbhq/relapsing) has announced the addition of the "Relapsing Remitting Multiple Sclerosis (RRMS) - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Relapsing Remitting Multiple Sclerosis (RRMS), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Relapsing Remitting Multiple Sclerosis (RRMS) and special features on late-stage and discontinued projects. The report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Companies Involved in Therapeutics Development - AbbVie Inc. - Actelion Ltd - Allozyne, Inc. - Amarna Therapeutics B.V. - Biogen Idec Inc. - Cognosci, Inc. - Eli Lilly and Company - F. Hoffmann-La Roche Ltd. - Genmab A/S - GlaxoSmithKline plc - MedImmune, LLC - Merck KGaA - Mitsubishi Tanabe Pharma Corporation - Neurotec Pharma SL - Novartis AG - Nuron Biotech, Inc. - Opexa Therapeutics, Inc. - Receptos, Inc. - RedHill Biopharma Ltd. - Synthetic Biologics, Inc. - Teva Pharmaceutical Industries Limited - Trophos SA - XenoPort, Inc. Drug Profiles: - laquinimod sodium - dimethyl fumarate - laquinimod sodium - fingolimod hydrochloride - ocrelizumab - interferon beta-1b - daclizumab - RPC-1063 - Epigallocatechin Gallate - GSK-239512 - siponimod - tabalumab - firategrast - ponesimod - plovamer acetate - estriol - imilecleucel-t - olesoxime - ofatumumab - RNS-60 - (rifabutin clarithromycin clofazimine) - diazoxide - MT-1303 - Boswellic Acids - VAY-736 - MEDI-551 - interferon beta-1b pegylated - XP-23829 - Pegylated Interferon-Beta-1b - COG-133 For more information visit http://www.researchandmarkets.com/research/p7dbhq/relapsing
Opexa Therapeutics to Attend the American Academy of Neurology Annual Meeting
Business Wire - Tue Apr 22, 7:01AM CDT
Opexa Therapeutics, Inc. (NASDAQ: OPXA), a biotechnology company developing Tcelna(R) (imilecleucel-T), a novel T-cell immunotherapy for the treatment of multiple sclerosis (MS), today announced its participation at the American Academy of Neurology (AAN) 2014 Annual Meeting taking place from April 26 to May 3, 2014 in Philadelphia. The AAN Annual Meeting is the world's largest gathering of neurologists, featuring breakthrough scientific research.
Brinson Patrick Re-launches Research Department
PR Newswire - Thu Apr 10, 7:21AM CDT
Brinson Patrick Securities Corporation ("Brinson Patrick"
announced today that the firm has re-launched its equity research department with the recent initiation of coverage on several life sciences companies. The research effort is being spearheaded by Christopher James, M.D., Managing Director and Senior Equity Research Analyst. Lawsuits, Clinical Studies, Financial Results, and Stock Movements - Analyst Notes on Idenix, BG Medicine, Progenics, Omeros, and Opexa
PR Newswire - Fri Mar 21, 7:00AM CDT
Today, Analysts Review released its analysts' notes regarding Idenix Pharmaceuticals Inc. (NASDAQ: IDIX), BG Medicine, Inc. (NASDAQ: BGMD), Progenics Pharmaceuticals Inc. (NASDAQ: PGNX), Omeros Corporation (NASDAQ: OMER), and Opexa Therapeutics, Inc. (NASDAQ: OPXA). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.AnalystsReview.com/register http://www.analystsreview.com/register
Opexa Therapeutics Appoints Prof. Hans-Peter Hartung and Timothy Barabe to the Board of Directors
Business Wire - Thu Mar 20, 7:01AM CDT
Opexa Therapeutics, Inc. (NASDAQ: OPXA), a biotechnology company developing Tcelna(R), a novel T-cell immunotherapy for the treatment of multiple sclerosis (MS), today announced the addition of two highly experienced individuals to join the Company's Board of Directors. Hans-Peter Hartung, MD, PhD, FRCP, a world leading clinician and expert in the treatment of Multiple Sclerosis and other neurological diseases, and Timothy Barabe, a proven CFO with global operational and financial expertise, have each been appointed to the Company's Board of Directors, effective March 19th.
Global Stem Cell Umbilical Cord Blood (UCB) Market to 2020
M2 - Mon Mar 10, 7:45AM CDT
Research and Markets (http://www.researchandmarkets.com/research/gsw6jj/global_stem_cell) has announced the addition of the "Global Stem Cell Umbilical Cord Blood (UCB) Market to 2020" report to their offering. The market is expected to reach revenue of $56.4 billion by 2020, growing at CAGR of 33.4% during 2013 to 2020 The study observed that the global umbilical cord blood stem cell market is forecasted to reach market value over $11.5 billion in 2014 from $ 6.5 billion in 2012. Developments and approvals for novel cord blood stem cells therapies is expected to drive the market growth. The storage service market was valued at $7.4 billion in 2013. Increase in prevalence rate of chronic diseases such as cancer, diabetes, blood disease, immune disease, metabolic disease etc. has increased the need of cost effective and efficient way of treatment. However, cord blood stem cells have the potential to treat these chronic diseases effectively. These stem cells have special property of higher cell count in lower blood volume. Collection of these stem cells is much easier than other stem cells and could be stored in specialized preservation facilities called as Cord Blood Stem Cell Banks.Cord blood stem cells market is in its emerging phase. Significant applications of stem cells in the treatment of various disorders will be commercialized very soon as most of them are in the last phase of clinical trials. Patents for collection techniques and therapeutics methods are approved by respective government of developed countries however patents for UCB stem cells are comparatively less in developing economies. According to lead analyst Debbie Shields, the geographic analysis shows that the North American market for cord blood stem cell would account for approx. 44% of total revenue generated by the cord blood market in 2013. However, much expected growth is to occur in Asia-Pacific regions during the forecast period, because of growing demand for chronic disease treatments and widely increasing awareness levels. This report study offers updated review about major market players present in this market such as researcher based pharmaceutical companies and therapeutics services companies. Key Market Segments Global Stem cell UCB market by storage - Public cord blood banks - Private cord blood banks - Public Vs. Private UCB banks Global Stem cell UCB market by Diseases - Cancer/ Oncology diseases - Acute Leukemia - Chronic Leukemia - High Risk Solid Tumors - Myelodysplastic Syndrome - Blood diseases - Aplastic Anemia - Beta Thalassemia - Sickle Cell disease - Immune Disorders - Leukocyte Adhesion Deficiency - Hystiocytic Disorders - Wiskott-Aldrich - Metabolic Disorders - Krabbe Disease - Hurler Syndrome - Sanfilippo Syndrome - Other diseases - Osteopetrosis - Hemophagoyticlymphohistiocytosis Global Stem cell UCB market by Technology - Stem Cell Transplant - Autologous transplant - Allogenic transplant - Transplant Medicine - Regenerative Medicine - Others - Cord Blood Banking - Blood Transfusion - Cell Based Genetics Companies Mentioned - Advanced Cell Technology Inc. (USA) - Athersys Inc. - California Stem Cell - Cytori Therapeutics Inc. - Geron Corporation - Mesoblast Limited - NeoStem Inc. - Opexa Therapeutics Inc. - Osiris Therapeutics - Pluristem Therapeutics Inc. For more information visit http://www.researchandmarkets.com/research/gs..._stem_cell
Opexa Therapeutics Reports Year End 2013 Financial Results and Provides Corporate Update
Business Wire - Thu Feb 27, 3:20PM CST
Opexa Therapeutics, Inc. (NASDAQ: OPXA), a biotechnology company developing a novel T-cell immunotherapy for multiple sclerosis (MS), today reported financial results for the year ended December 31, 2013, and provided an overview of recent corporate developments.
Opexa Therapeutics Announces News Release and Conference Call Schedule to Discuss Year End 2013 Financial Results
Business Wire - Wed Feb 26, 7:02AM CST
Opexa Therapeutics, Inc. (NASDAQ: OPXA), a biotechnology company developing Tcelna(R), a novel T-cell immunotherapy for the treatment of multiple sclerosis (MS), today announced that the Company will report financial results for the year ended December 31, 2013, at the close of trading on Thursday, February 27, 2014. The Company will also conduct a conference call and webcast to discuss financial results and provide a corporate update at 4:30 P.M. EST on Thursday, February 27.
Opexa Therapeutics CEO to Present at the 2014 Leerink Global Healthcare Conference
Business Wire - Tue Feb 11, 1:16PM CST
Opexa Therapeutics, Inc. (NASDAQ: OPXA), a biotechnology company developing Tcelna(R), a novel T-cell immunotherapy for the treatment of multiple sclerosis (MS), today announced that Neil K. Warma, President and Chief Executive Officer, will present at the 2014 Leerink Global Healthcare Conference on Wednesday, February 12, 2014, at 1:00 p.m. EST in the Metropolitan Suite. The conference will be held at the Waldorf-Astoria Hotel in New York, NY.
Opexa Therapeutics to Present at the 16th Annual BIO CEO & Investor Conference
Business Wire - Wed Jan 29, 8:00AM CST
Opexa Therapeutics, Inc. (NASDAQ: OPXA), a biotechnology company developing Tcelna(R), a novel T-cell immunotherapy for the treatment of multiple sclerosis (MS), today announced that Neil K. Warma, President and Chief Executive Officer, will present at the 16th Annual BIO CEO & Investor Conference on Monday, February 10, 2014, at 11:30 a.m. EST in the Conrad Room. The conference will be held at the Waldorf=Astoria Hotel in New York, NY.
Opexa Therapeutics Chief Scientific Officer Invited as Guest Speaker at the Phacilitate Cell & Gene Therapy Forum
Business Wire - Thu Jan 23, 8:00AM CST
Opexa Therapeutics, Inc. (NASDAQ: OPXA), a biotechnology company developing Tcelna(R), a novel T-cell immunotherapy for the treatment of multiple sclerosis (MS), today announced that Don Healey, Ph.D., Opexa's Chief Scientific Officer, has been invited as a guest speaker to participate in the Phacilitate Cell & Gene Therapy Forum. The event will take place January 27-29, 2014, at The Grand Hyatt in Washington, DC.
Opexa Therapeutics Inc concludes public offering of 4.12m common shares, including the exercise of over-allotment option
M2 - Tue Dec 24, 8:57AM CST
Biotechnology company Opexa Therapeutics Inc (NasdaqCM:OPXA) revealed on Monday the completion of an underwritten public offering of 4,120,000 shares of its common stock,
Opexa Therapeutics, Inc. Announces Closing of Public Offering of Common Stock and Full Exercise of Underwriters' Option to Purchase Additional Shares
Business Wire - Mon Dec 23, 9:18AM CST
Opexa Therapeutics, Inc. (NASDAQ: OPXA), a biotechnology company developing Tcelna(R), a patient-specific T-cell immunotherapy for the treatment of multiple sclerosis (MS), today announced the closing of the previously announced underwritten public offering of 4,120,000 shares of its common stock, including the full exercise of the over-allotment option granted to the underwriters to purchase an additional 618,000 shares of its common stock, at a price to the public of $1.70 per share. The gross proceeds to Opexa from this offering were $8,054,600, before deducting underwriting discounts and commissions and other estimated offering expenses and including the full exercise of the over-allotment option. All of the shares in the offering were sold by Opexa.
Apricus Biosciences Inc receives national phase approval for erectile dysfunction cream Vitaros in France
M2 - Fri Dec 20, 5:36AM CST
Pharmaceutical company Apricus Biosciences Inc (NasdaqCM:APRI) reported on Thursday the receipt of National Agency for Medicines and Health Products Safety's (ANSM) national phase approval for Vitaros for the treatment of patients with erectile dysfunction (ED) in France.
Opexa Therapeutics Inc prices public offering at USD1.70 per share
M2 - Wed Dec 18, 3:24AM CST
Biotechnology company Opexa Therapeutics Inc (NasdaqCM:OPXA) said on Tuesday that it has priced an underwritten public offering of 4.12m shares of its common stock.
Opexa Therapeutics, Inc. Announces Pricing of Public Offering of Common Stock
Business Wire - Tue Dec 17, 8:15PM CST
Opexa Therapeutics, Inc. (NASDAQ:OPXA), a biotechnology company developing Tcelna(R), a patient-specific T-cell immunotherapy for the treatment of multiple sclerosis (MS), today announced the pricing of an underwritten public offering of 4.12 million shares of its common stock at a price to the public of $1.70 per share. The gross proceeds to Opexa from this offering are expected to be approximately $7 million, before deducting underwriting discounts and commissions and other estimated offering expenses. All of the shares in the offering are to be sold by Opexa. Opexa has also granted the underwriters a 45-day option to purchase up to an additional 618,000 shares of common stock to cover over-allotments, if any. The offering is expected to close on or about December 23, 2013, subject to customary closing conditions.
